Thanks! My personal opinion is that 1) Yes, forgone conclusion because they got the reasons for allowance days earlier 2) from a presentation: "no notable difference between ANAVEX 2-73 and ANAVEX 2-73 with donepezil observed" 3) if you read the patent banter, this patent may be for a very narrow dose range, which might make it easier for competitors to find a similar combination dose that AVXL does hold patent on

But - if avxl is looking to partner, 1) this would one of the item they would want to secure 2) it also sets precedent for other possible combinations with other drugs that could be patented with A 2-73